Global Psoriatic Arthritis Treatment Market Report 2023: Recent Development of Interleukin-17 Inhibitors Drives Growth - ResearchAndMarkets.com

It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, April 18, 2023
Information
Tags: 
Health, Other Health, Secukinumab, Psoriatic arthritis, Arthritis mutilans, Arthritis, Spondylitis, Public, Tendinopathy, Arthritis Foundation, Psoriasis, Woman, Brodalumab, UCB, Dactylitis, Patient, Celgene, Certolizumab pegol, Ixekizumab, Diagnosis, Skin, Disease, Pharmaceutical industry
Geotags: 
ASIA, NORTH AMERICA, EUROPE
⚠ generated by AI ↴
Organisation: 
RESEARCH AND MARKETS, RESEARCHANDMARKETS.COM
Summary
Key Points: 
  • It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.
  • The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors.
  • Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis.
  • The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis.


The "Psoriatic Arthritis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031" report has been added to ResearchAndMarkets.com's offering.

The psoriatic Arthritis Treatment Market is projected to expand at a CAGR of 7.5% between 2023 and 2031.

Companies Mentioned

  • Abbvie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • F.Hoffman La-Roche AG
  • Janssen Global Services
  • Merck & Co.
  • Novartis AG
  • Valeant Pharmaceuticals International Inc.

This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.

The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease that primarily affects the skin. Majorly 30% of the patients suffering from psoriasis develop psoriatic arthritis during the later stages of the disease. Psoriatic arthritis affects men and women equally with a global prevalence rate of 6 per 100,000 people. It is a heterogeneous disease and is categorized into 5 subtypes, namely, symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans.

The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors. The occurrence is high in the Caucasian populations of North America and Europe followed by Asia Pacific.

According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering from psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease such as mild, moderate, or severe psoriatic arthritis.

The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab have better drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.) and Aprelimast (Celgene Corporation), and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2022 to 2030 and capitalize the psoriatic arthritis treatment market.

Market Segmentation

Drug Class

  • TNF Inhibitors
  • Interleukin Inhibitors
  • PDE4 Inhibitors
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of the Psoriatic Arthritis Treatment market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Psoriatic Arthritis Treatment market?
  • Which is the largest regional market for the Psoriatic Arthritis Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Psoriatic Arthritis Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Psoriatic Arthritis Treatment market worldwide?

For more information about this report visit https://www.researchandmarkets.com/r/34fn9z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Copyright: 
Copyright Business Wire 2023